Jaswinder Matharu

Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and over the counter products for the North American market. Our vision is to deliver high quality products at affordable prices by leveraging global partnerships with the best FDA approved manufacturing facilities across the world. Our sales and marketing personnel are among the best in the world. The US generic prescription market is currently at approximately $60 billion, and over $120 billions worth of products will be coming off of patent protection in next 10 years. Nivagen believes that, with its strategic partnership model of global alliances with highly efficient pharmaceutical companies across the globe, we can provide cost savings to the consumer while creating value for all members of the supply chain. Nivagen is focused in three areas of product development: development/co-development, acquisition/in-licensing, and providing sales and marketing services. We are actively looking to partner with CRO and CRAM to co-develop products. We are also acquiring existing products. If you are small FDA qualified manufacturer and want to launch your company or product in the US, Nivagen can provide complete turnkey solutions and cost effective delivery on an accelerated timeline.

r4 is the pioneer of cross-enterprise AI. Organizations across multiple industries use r4’s platform to unlock growth opportunities trapped in and between enterprise silos, systems, and processes. Cross-enterprise AI does that by bringing together data from across the enterprise, regardless of location or format, in a secure private cloud. Then it adds external data – on customer segments, locations, distribution models, and many other variables—to create a completely new and unified model of a business and its markets. Cross-enterprise AI deeply analyzes this information, uncovers new revenue opportunities that could never be seen before, and delivers a set of predictions and targeted recommendations that can be automatically fed back into enterprise systems as instructions. r4 was created by the founders of priceline.com and key Priceline executives to leverage Priceline’s breakthroughs in applying predictive algorithms on a mass scale to extract profit from data. Their vision and innovations pioneered e-commerce as a business model and revolutionized the travel industry. The r4 team is now applying this same DNA to help large companies apply cross-enterprise AI to drive growth and create competitive advantages. r4's operations are headquartered in Connecticut, with presence in Metropolitan New York, San Francisco, Austin and Washington, DC. European operations are headquartered in Dublin, with presence in Munich and London.

Octo is a technology firm dedicated to solving the Federal Government’s most complex challenges, enabling agencies to jump the technology curve. We don’t just modernize. We create lasting change through best practices that help agencies implement and integrate at-scale next-generation technology and innovation. With a mission and service first mentality, we provide Agile, DevSecOps, Artificial Intelligence, Cybersecurity, Blockchain, Cloud, Open Source, and Data Science solutions, collaborating to solve customers’ pressing problems. Headquartered in Reston, Virginia, Octo delivers proven technology vital to the intelligence community and health care, defense, national security, and civilian agencies that directly impact our nation.

Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and over the counter products for the North American market. Our vision is to deliver high quality products at affordable prices by leveraging global partnerships with the best FDA approved manufacturing facilities across the world. Our sales and marketing personnel are among the best in the world. The US generic prescription market is currently at approximately $60 billion, and over $120 billions worth of products will be coming off of patent protection in next 10 years. Nivagen believes that, with its strategic partnership model of global alliances with highly efficient pharmaceutical companies across the globe, we can provide cost savings to the consumer while creating value for all members of the supply chain. Nivagen is focused in three areas of product development: development/co-development, acquisition/in-licensing, and providing sales and marketing services. We are actively looking to partner with CRO and CRAM to co-develop products. We are also acquiring existing products. If you are small FDA qualified manufacturer and want to launch your company or product in the US, Nivagen can provide complete turnkey solutions and cost effective delivery on an accelerated timeline.

Founded by Shri I.A. Modi, Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last seven decades, the company has been developing and manufacturing pharmaceutical products in India and selling and distributing these in over hundred other countries around the world. Focused strongly on Innovation and Research, the company is present in more than forty-five therapeutic areas spread across twelve specialities, including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. At Cadila Pharmaceuticals, Research and Development is at the core of all its initiatives, be it Biotechnology, APIs, Formulations, Plant Tissue Culture or Phytochemistry. More than 300 scientists in its various Research and Development setups reinforce the competitiveness of research in the therapeutic areas which have high unmet medical needs. Cadila Pharmaceuticals Excellence in manufacturing facilities is central to Cadila Pharmaceuticals. The company’s formulations manufacturing plant at Dholka near Ahmedabad, Gujarat is spread over hundred acres of land. This state-of-the- art facility is not only impressive in size, but is also USFDA approved. The second formulations manufacturing facility is located at Samba in Jammu and Kashmir. The facility meets most of the stringent quality standards across the globe to produce tablets, capsules, soft and hard gelatin capsules, liquids and orals. Two Active Pharmaceutical Ingredient (API) manufacturing units at Ankleshwar, Gujarat manufacture a wide range of APIs and intermediates including many USFDA-certified products. The company has strong foothold in the African continent through its formulation manufacturing facility at Addis Ababa in Ethiopia. For more information visit: https://www.cadilapharma.com/

r4 is the pioneer of cross-enterprise AI. Organizations across multiple industries use r4’s platform to unlock growth opportunities trapped in and between enterprise silos, systems, and processes. Cross-enterprise AI does that by bringing together data from across the enterprise, regardless of location or format, in a secure private cloud. Then it adds external data – on customer segments, locations, distribution models, and many other variables—to create a completely new and unified model of a business and its markets. Cross-enterprise AI deeply analyzes this information, uncovers new revenue opportunities that could never be seen before, and delivers a set of predictions and targeted recommendations that can be automatically fed back into enterprise systems as instructions. r4 was created by the founders of priceline.com and key Priceline executives to leverage Priceline’s breakthroughs in applying predictive algorithms on a mass scale to extract profit from data. Their vision and innovations pioneered e-commerce as a business model and revolutionized the travel industry. The r4 team is now applying this same DNA to help large companies apply cross-enterprise AI to drive growth and create competitive advantages. r4's operations are headquartered in Connecticut, with presence in Metropolitan New York, San Francisco, Austin and Washington, DC. European operations are headquartered in Dublin, with presence in Munich and London.

Octo is a technology firm dedicated to solving the Federal Government’s most complex challenges, enabling agencies to jump the technology curve. We don’t just modernize. We create lasting change through best practices that help agencies implement and integrate at-scale next-generation technology and innovation. With a mission and service first mentality, we provide Agile, DevSecOps, Artificial Intelligence, Cybersecurity, Blockchain, Cloud, Open Source, and Data Science solutions, collaborating to solve customers’ pressing problems. Headquartered in Reston, Virginia, Octo delivers proven technology vital to the intelligence community and health care, defense, national security, and civilian agencies that directly impact our nation.